Javier Munoz

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/9633689/javier-munoz-publications-by-year.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

51	2,927	12	52
papers	citations	h-index	g-index
52 ext. papers	4,132 ext. citations	8.3 avg, IF	4.35 L-index

#	Paper	IF	Citations
51	Zanubrutinib in lymphoproliferative disorders: a comprehensive review. <i>Therapeutic Advances in Hematology</i> , 2022 , 13, 204062072210939	5.7	1
50	Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2021 ,	59.2	45
49	Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. <i>Blood Advances</i> , 2021 ,	7.8	6
48	Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives. <i>Targeted Oncology</i> , 2021 , 16, 295-308	5	3
47	Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Klinhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202). <i>Leukemia and Lymphoma</i> , 2021 , 62, 368-376	1.9	12
46	Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL) <i>Journal of Clinical Oncology</i> , 2020 , 38, 8008-8008	2.2	33
45	Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. <i>American Journal of Hematology</i> , 2020 , 95, 362-371	7.1	50
44	Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017 , 377, 2531-2544	59.2	2326
43	Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 78, 167-71	3.5	11
42	Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 533-47	6.1	46
41	Androgen receptors beyond prostate cancer: an old marker as a new target. <i>Oncotarget</i> , 2015 , 6, 592-6	03 .3	29
40	Concise review: umbilical cord blood transplantation: past, present, and future. <i>Stem Cells Translational Medicine</i> , 2014 , 3, 1435-43	6.9	63
39	STAT3 inhibitors: finding a home in lymphoma and leukemia. <i>Oncologist</i> , 2014 , 19, 536-44	5.7	48
38	Erdheim-Chester disease: characteristics and management. <i>Mayo Clinic Proceedings</i> , 2014 , 89, 985-96	6.4	50
37	Progression of double-hit lymphoma in the midst of R-hyper CVAD. <i>American Journal of Hematology</i> , 2013 , 88, 87-8	7.1	3
36	Molecular profiling and the reclassification of cancer: divide and conquer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , 127-34	7.1	20
35	Mucormycosis-associated intracranial hemorrhage. <i>Blood Coagulation and Fibrinolysis</i> , 2013 , 24, 100-1	1	6

34	A tale of two histiocytic disorders. <i>Oncologist</i> , 2013 , 18, 2-4	5.7	9
33	Posterior reversible encephalopathy syndrome: more than meets the eye. <i>Journal of Clinical Oncology</i> , 2013 , 31, e360-3	2.2	8
32	Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. <i>Journal of Clinical Oncology</i> , 2013 , 31, e351-2	2.2	53
31	Molecular Profiling and the Reclassification of Cancer: Divide and Conquer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , 33, 127-	134 ¹	11
30	Leukocytosis: the mysteries within. American Journal of Hematology, 2012, 87, 197	7.1	
29	Blastic plasmacytoid dendritic cell neoplasm. American Journal of Hematology, 2012, 87, 710	7.1	4
28	Histiocytic sarcoma of the thyroid. American Journal of Hematology, 2012 , 87, 531	7.1	9
27	CNS hyperleukocytosis. <i>Blood</i> , 2012 , 119, 5953	2.2	2
26	Leukemic phase of Burkitt lymphoma. <i>Blood</i> , 2012 , 120, 247	2.2	
25	Lymphocytosis: T-cell large granular lymphocyte leukemia. <i>Blood</i> , 2012 , 120, 1543	2.2	2
24	Reactive eosinophilia and thrombosis. <i>Blood</i> , 2012 , 120, 2785	2.2	1
23	Targeted therapy in rare cancersadopting the orphans. <i>Nature Reviews Clinical Oncology</i> , 2012 , 9, 631-	- 42 9.4	25
22	Cytomegalovirus-induced haemophagocytic lymphohistiocytosis syndrome. <i>BMJ Case Reports</i> , 2012 , 2012,	0.9	4
21	Umour-induced osteomalaciaU <i>BMJ Case Reports</i> , 2012 , 2012,	0.9	8
20	Salmonella-related mycotic aortic aneurysm heralding a diagnosis of multiple myeloma. <i>American Journal of Hematology</i> , 2012 , 87, 820-1	7.1	1
19	Relapse of liver amyloidosis 6 years after autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2012 , 87, 926	7.1	О
18	The dilemma of inherited dysfibrinogenemia during pregnancy. <i>Blood Coagulation and Fibrinolysis</i> , 2012 , 23, 775-7	1	6
17	Antibiotic-refractory sinusitis. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 308, 2399-400	27.4	2

16	Blue sclerae. JAMA - Journal of the American Medical Association, 2012, 307, 1310-1	27.4	
15	Rash in an immunocompromised patient. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 307, 612-3	27.4	2
14	Familial history of bone tumors. JAMA - Journal of the American Medical Association, 2012, 308, 1476-7	27.4	
13	A pain in the neck. JAMA - Journal of the American Medical Association, 2012, 308, 182-3	27.4	
12	Sister Mary Joseph d nodule. BMJ Case Reports, 2011, 2011,	0.9	1
11	Paraneoplastic syndromes associated to Hodgkinla lymphoma. BMJ Case Reports, 2011,	0.9	
10	Basophilic stippling: a lead to the diagnosis. <i>Blood</i> , 2011 , 118, 5370	2.2	2
9	Iron-overload myopathy. International Journal of Hematology, 2011 , 94, 503-4	2.3	3
8	Epidermal growth factor receptor-induced hirsutism and trichomegaly. <i>Mayo Clinic Proceedings</i> , 2011 , 86, e50	6.4	5
7	Severe lactic acidosis in a patient with metastatic prostate cancer. <i>Journal of Cancer Research and Therapeutics</i> , 2011 , 7, 201-2	1.2	11
6	The Prognostic Implications of Nucleated Red Blood Cells in Myelodysplastic Syndrome. <i>Blood</i> , 2011 , 118, 5058-5058	2.2	1
5	Risk of Venous Thromboembolism in Patients with Myelodysplatic Syndrome. <i>Blood</i> , 2011 , 118, 5245-52	2452	
4	Impact of the Approval of Eculizumab by the Food and Drug Administration on the Frequency of Patients Screened for Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2011 , 118, 4377-4377	2.2	
3	The Relevance of Increased Tonsil Uptake When Restaging Lymphoma with Positron Emission Tomography. <i>Blood</i> , 2010 , 116, 3133-3133	2.2	1
2	The Role of Digital Tomosynthesis In the Staging of Newly Diagnosed Multiple Myeloma: Preliminary Data. <i>Blood</i> , 2010 , 116, 4057-4057	2.2	
1	The Significance of Hepatic Iron Overload in Allogenic Stem Cell Transplant Recipients <i>Blood</i> , 2009 , 114, 4313-4313	2.2	